Vivani Medical Appoints Anthony Baldor as CFO
Company - People | Jun 11, 2025 | EIN
Vivani Medical, Inc., a biopharmaceutical company known for its innovative drug implants, announces the appointment of Anthony Baldor as the new Chief Financial Officer. Baldor brings over two decades of financial expertise, having successfully led significant fundraising initiatives and strategic developments in the biotechnology sector. This appointment follows the retirement of Brigid A. Makes, who was instrumental in the company's transformative merger accomplishments. CEO Adam Mendelsohn expressed his excitement for Baldor's role in the company's growth, underscoring the potential of their NanoPortal platform and emerging therapeutic solutions. These include cutting-edge implants like NPM-115 for weight management and others for diabetes control. Additionally, the company addresses medication adherence challenges with these long-acting implants, a major concern given the healthcare costs and outcomes linked to this issue. Vivani is also exploring strategic business moves, such as a potential spinoff of its subsidiary, Cortigent, despite inherent risks and regulatory uncertainties. Forward-looking statements regarding product advancements and financial projections highlight opportunities and emphasize the company's dedication to improving patient treatment options.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United States – Vivani Medical is based in the U.S., and the article discusses activities and strategic moves primarily occurring within this country.
Industry
- Biotechnology – The industry involves companies that create products and technologies in the field of biology, often focusing on drug development and medical technologies, as is the case with Vivani's drug implants.
- Pharmaceuticals – Vivani Medical operates within this sector as it develops drug delivery solutions aimed at treating chronic conditions through advanced long-acting implantable technology.
- Healthcare – The article's focus on patient adherence and chronic disease management solutions situates it within the broader healthcare sector, where technological advancements improve treatment outcomes.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Vivani Medical, Inc. | Company | Company | A clinical-stage biopharmaceutical company focused on developing drug implants for chronic disease management. |
| Anthony Baldor | New CFO | Person | Appointed as the new Chief Financial Officer of Vivani Medical, bringing extensive financial expertise from the biotech sector. |
| Brigid A. Makes | Retiring CFO | Person | Former CFO retiring from Vivani Medical to focus on board duties and personal interests. |
| Adam Mendelsohn | CEO | Person | Chief Executive Officer of Vivani Medical, overseeing the company's strategic direction and growth. |
| Nano Precision Medical | Merged Entity | Company | Part of a successful merger with Second Sight Medical Products to form Vivani Medical. |
| Second Sight Medical Products | Merged Entity | Company | Merged with Nano Precision Medical to form Vivani Medical. |
| Cortigent, Inc. | Subsidiary | Company | A wholly owned subsidiary of Vivani Medical that is planned to be spun off. |